NASDAQ:NTEC - Intec Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intec Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.26 +0.02 (+8.23 %) (As of 02/28/2020 10:22 AM ET) Add Compare Today's Range$0.24Now: $0.26▼$0.2750-Day Range$0.24MA: $0.38▼$0.5652-Week Range$0.23Now: $0.26▼$8.99Volume729,888 shsAverage Volume2.14 million shsMarket Capitalization$8.69 millionP/E RatioN/ADividend YieldN/ABeta-0.05 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTEC Previous Symbol CUSIPN/A CIK1638381 Webhttp://www.intecpharma.com/ Phone972-2586-4657Debt Debt-to-Equity RatioN/A Current Ratio1.57 Quick Ratio1.57Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.63 per share Price / Book0.16Profitability EPS (Most Recent Fiscal Year)($1.40) Net Income$-43,540,000.00 Net MarginsN/A Return on Equity-116.85% Return on Assets-89.67%Miscellaneous Employees70 Outstanding SharesN/AMarket Cap$8.69 million Next Earnings DateN/A OptionableOptionable Receive NTEC News and Ratings via Email Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NTEC Rates by TradingView Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions What is Intec Pharma's stock symbol? Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC." How were Intec Pharma's earnings last quarter? Intec Pharma Ltd (NASDAQ:NTEC) released its earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.10. View Intec Pharma's Earnings History. What price target have analysts set for NTEC? 5 brokerages have issued 1-year price targets for Intec Pharma's stock. Their forecasts range from $1.00 to $16.00. On average, they expect Intec Pharma's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 4,210.3% from the stock's current price. View Analyst Price Targets for Intec Pharma. What is the consensus analysts' recommendation for Intec Pharma? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intec Pharma. What are Wall Street analysts saying about Intec Pharma stock? Here are some recent quotes from research analysts about Intec Pharma stock: 1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (2/4/2020) 2. LADENBURG THALM/SH SH analysts commented, "We are modeling mid-’19 cash is sufficient to fund operations till late 2020. While we appreciate Accordion Pill’s controlled-release abilities and still find AP-CBD/THC’s PK results vs. Sativex as impressive (290-330% and 25-50% higher exposures of CBD and THC, respectively, than Sativex), we have little insight into how the AP-Novartis Phase 1 may come out. Intec’s collaboration on an undisclosed compound was announced. Intec reported it successfully developed an a proprietary Novartis compound that met the prerequisite in vitro specifications. In 1Q’19 a human PK began, with the expectation for completion of the study and the results this summer, with Novartis making a go/no-go decision on a Phase 2 this fall." (8/12/2019) 3. Maxim Group analysts commented, "Intec announced the presentation of the results from its PK study on AP-CD/ LD (Accordion Pill – Carbidopa/Levodopa) in Parkinson’s disease (PD) at the XXIV Related Disorders. The data was originally reported on 2/19 (see note, LINK), however, additional detail was provided in the presentation." (6/20/2019) Has Intec Pharma been receiving favorable news coverage? News stories about NTEC stock have trended very negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intec Pharma earned a coverage optimism score of -3.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Intec Pharma. Are investors shorting Intec Pharma? Intec Pharma saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 934,200 shares, an increase of 25.9% from the January 15th total of 741,800 shares. Based on an average daily trading volume, of 460,300 shares, the days-to-cover ratio is currently 2.0 days. Currently, 3.2% of the shares of the stock are sold short. View Intec Pharma's Current Options Chain. Who are some of Intec Pharma's key competitors? Some companies that are related to Intec Pharma include RegeneRx Biopharmaceuticals (RGRX), Evoke Pharma (EVOK), Jaguar Health (JAGX), Adamis Pharmaceuticals (ADMP), Annovis Bio (ANVS), Alimera Sciences (ALIM), Akari Therapeutics (AKTX), Fibrocell Science (FCSC), Moleculin Biotech (MBRX), Pulmatrix (PULM), Celsion (CLSN), Edesa Biotech (EDSA), Addex Therapeutics (ADDXF), Aerpio Pharmaceuticals (ARPO) and China SXT Pharmaceuticals (SXTC). What other stocks do shareholders of Intec Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include SCYNEXIS (SCYX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), AbbVie (ABBV), Canopy Growth (CGC), Cara Therapeutics (CARA), NVIDIA (NVDA) and Zynerba Pharmaceuticals (ZYNE). Who are Intec Pharma's key executives? Intec Pharma's management team includes the folowing people: Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 52)Mr. Nir Sassi, Chief Financial Officer (Age 43)Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 50)Mr. Walt Addison Linscott, Chief Bus. Officer (Age 58)Dr. R. Michael Gendreau, Chief Medical Officer (Age 63) When did Intec Pharma IPO? (NTEC) raised $30 million in an initial public offering (IPO) on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO. Who are Intec Pharma's major shareholders? Intec Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include AdvisorShares Investments LLC (1.17%), Harel Insurance Investments & Financial Services Ltd. (1.12%) and Phoenix Holdings Ltd. (0.44%). Company insiders that own Intec Pharma stock include Anthony J Maddaluna, Issac Silberman, Jeffrey A Meckler and Pharma Technologies Ltd Dexcel. View Institutional Ownership Trends for Intec Pharma. Which major investors are selling Intec Pharma stock? NTEC stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd.. Company insiders that have sold Intec Pharma company stock in the last year include Issac Silberman and Pharma Technologies Ltd Dexcel. View Insider Buying and Selling for Intec Pharma. Which major investors are buying Intec Pharma stock? NTEC stock was purchased by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC and Phoenix Holdings Ltd.. Company insiders that have bought Intec Pharma stock in the last two years include Anthony J Maddaluna and Jeffrey A Meckler. View Insider Buying and Selling for Intec Pharma. How do I buy shares of Intec Pharma? Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Intec Pharma's stock price today? One share of NTEC stock can currently be purchased for approximately $0.26. How big of a company is Intec Pharma? Intec Pharma has a market capitalization of $8.69 million. The biotechnology company earns $-43,540,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Intec Pharma employs 70 workers across the globe.View Additional Information About Intec Pharma. What is Intec Pharma's official website? The official website for Intec Pharma is http://www.intecpharma.com/. How can I contact Intec Pharma? Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected] MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 260 (Vote Outperform)Underperform Votes: 297 (Vote Underperform)Total Votes: 557MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: How to interpret the current ratio
